Brit J Cancer:二甲双胍能预防胃腺癌吗?

2019-10-12 xing.T MedSci原创

由此可见,该随访时间小于10年的队列研究表明二甲双胍的使用可能无法预防胃腺癌。

目前尚不清楚二甲双胍是否可以降低患腺癌的风险。近日,肿瘤领域权威杂志British Journal of Cancer上发表了一篇研究文章,该研究是在2005年至2015年期间进行的一项基于人群的队列研究。研究人员在两个队列中评估了二甲双胍的使用与非贲门部位和贲门部位腺癌之间的相关性。

研究人员使用了服用抗糖尿病药物治疗的糖尿病队列,以及与之相匹配的普通药物使用者队列,其中非二甲双胍的使用者与性别和年龄类似的二甲双胍使用者以10:1的比例进行匹配。多变量Cox比例风险回归分析提供了风险比(HR)和95%置信区间(CI),针对性别、年龄、年份、合并症、幽门螺杆菌根除治疗、使用非甾体抗炎药或阿司匹林进行了调整。

在为期5.8年的中位随访中,糖尿病队列的892名参与者(0.1%)和普通药物使用者匹配队列中的6395名(0.1%)参与者发生了胃腺癌。与两个队列中未使用二甲双胍的人群比较,二甲双胍的使用者患胃非贲门部位腺癌(糖尿病队列:HR为0.93,95%CI为0.78–1.12;相匹配的队列:HR为1.30,95%CI为1.18-1.42)或贲门部位腺癌(糖尿病队列:HR为1.49,95%CI为1.09–2.02;相匹配的队列:HR为1.58,95%CI为1.38–1.81)发生风险并未显著降低。

由此可见,该随访时间小于10年的队列研究表明二甲双胍的使用可能无法预防胃腺癌。 

原始出处:

Jiaojiao Zheng.et al.Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study.British Journal of Cancer.2019.https://www.nature.com/articles/s41416-019-0598-z

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=899479, encodeId=aecc8994e943, content=该随访时间小于10年的队列研究表明<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>的使用可能无法预防<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>。也可能与随访时间比较短有关吧 , beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 16 08:44:10 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797873, encodeId=48521e9787302, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Oct 20 09:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305930, encodeId=6c87130593001, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 14 06:27:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041489, encodeId=c2481041489c2, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 18:27:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2020-11-16 lovetcm

    该随访时间小于10年的队列研究表明#二甲双胍#的使用可能无法预防#胃癌#。也可能与随访时间比较短有关吧

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=899479, encodeId=aecc8994e943, content=该随访时间小于10年的队列研究表明<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>的使用可能无法预防<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>。也可能与随访时间比较短有关吧 , beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 16 08:44:10 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797873, encodeId=48521e9787302, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Oct 20 09:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305930, encodeId=6c87130593001, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 14 06:27:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041489, encodeId=c2481041489c2, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 18:27:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=899479, encodeId=aecc8994e943, content=该随访时间小于10年的队列研究表明<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>的使用可能无法预防<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>。也可能与随访时间比较短有关吧 , beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 16 08:44:10 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797873, encodeId=48521e9787302, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Oct 20 09:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305930, encodeId=6c87130593001, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 14 06:27:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041489, encodeId=c2481041489c2, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 18:27:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=899479, encodeId=aecc8994e943, content=该随访时间小于10年的队列研究表明<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>的使用可能无法预防<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>。也可能与随访时间比较短有关吧 , beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Nov 16 08:44:10 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797873, encodeId=48521e9787302, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Oct 20 09:27:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305930, encodeId=6c87130593001, content=<a href='/topic/show?id=4f25833660c' target=_blank style='color:#2F92EE;'>#胃腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83366, encryptionId=4f25833660c, topicName=胃腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 14 06:27:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041489, encodeId=c2481041489c2, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Oct 12 18:27:00 CST 2019, time=2019-10-12, status=1, ipAttribution=)]
    2019-10-12 misszhang

    二甲双胍,神药!

    0

相关资讯

Lancet:早期使用Vildagliptin联合二甲双胍有助于糖尿病患者血糖控制

研究认为,早期联合使用vildagliptin和二甲双胍可实现新诊断II型糖尿病患者获得长期治疗收益

如果二甲双胍进国家集采

大家都在猜,第二轮国家集采啥时开始,会涉及哪些品种。

Circulation:二甲双胍与有无心衰/肾功能不全的糖尿病患者预后的相关性

二甲双胍是治疗2型糖尿病的一线药物,但其对心血管系统的作用尚未得到证实。研究人员对SAVOR-TIMI 53试验(沙格列汀与2型糖尿病患者的心血管预后)的患者(12156位)进行二次分析,评估二甲双胍暴露与预后的相关性。在12156位患者中,8971位(74%)有二甲双胍暴露,1611位(13%)有心衰史,1332位(11%)至少有中度的慢性肾病(估计肾小球滤过率≤45 mL·min?1·1.73

JAMA :二甲双胍对肾功能减退的糖尿病患者安全性良好

研究发现,在坚持单药治疗的糖尿病伴肾功能下降患者中,二甲双胍治疗与磺脲类药物相比,MACE风险更低

JAMA Oncology:二甲双胍抗癌实锤!临床试验证实,二甲双胍+靶向药一线治疗,可将携带EGFR突变晚期肺癌患者的生存期延长14个月

一项由墨西哥国立癌症研究所开展的临床II期试验证实,对存在EGFR突变的晚期肺腺癌患者,同时使用二甲双胍和靶向药进行一线治疗,可以将患者的生存期延长14个月!

EASD2019:重磅!VERIFY研究结果公布:早期联合可显著减少T2DM起始治疗失败相对风险49%

2019年9月18日,一项为期5年、全球多中心、随机、平行对照、双盲临床研究(VERIFY)结果在第55届欧洲糖尿病研究协会(EASD)年会上公布,并同时发表在当天出版的Lancet上。研究结果显示,针对新诊断2型糖尿病(T2DM)患者早期应用维格列汀与二甲双胍联合治疗,比单独应用二甲双胍(目前新诊断T2DM患者治疗标准)能更好地长期控制血糖,降低治疗失败率。